MindRank Doses First Patient in Phase III Trial of AI-Designed Oral GLP-1

MindRank Doses First Patient in Phase III Trial of AI-Designed Oral GLP-1

By, Admin 3 March 2026

The GLP-1 race just added another serious contender. MindRank has announced that the first patient has been dosed in the phase III trial of MDR-001, its artificial intelligence-designed oral GLP-1 receptor agonist (GLP-1RA) for obesity and type 2 diabetes in China.

If successful, MDR-001 could position itself as a differentiated, small-molecule alternative in a market dominated by injectable and peptide-based therapies.

The Phase III Study: MOBILE

The pivotal study, called MOBILE, is designed to evaluate the long-term efficacy and safety of MDR-001.

Key details:

  • Multicenter, randomized, double-blind, placebo-controlled
  • ~750 patients
  • 50 clinical centers across China
  • Led by Professor Linong Ji of Peking University People’s Hospital

This trial marks a critical step toward potential regulatory approval in China.

What Makes MDR-001 Different?

MDR-001 is not just another GLP-1. It is:

  • A biased, selective oral GLP-1 receptor agonist
  • A small molecule
  • Designed and optimized using artificial intelligence

In a completed phase IIb study, MDR-001 demonstrated:

  • Clinically meaningful efficacy
  • Favorable tolerability
  • Improvements in cardiometabolic parameters

These results supported advancement into phase III.

From AI Concept to Phase III in 4.5 Years

One of the most notable aspects of this program is speed.

  • Project initiation to U.S. IND clearance: 19 months
  • Advancement to phase III: ~4.5 years

MDR-001 was identified and optimized using MindRank’s proprietary platform, Molecule Pro, an end-to-end AI-driven drug discovery system.

Inside the AI Engine

MindRank’s discovery approach combines:

  • PharmKG biological knowledge graph
  • Protein dynamic simulation modeling (Molecule Dance)
  • Generative AI for molecular design
  • ADMET prediction modules
  • Iterative wet-lab validation

The platform enabled:

  • Deep analysis of GPCR protein–small molecule binding
  • Quantification of pathway-specific activity
    • cAMP agonism
    • Biased ß-arrestin 2 recruitment
  • Multi-objective optimization of:
    • Activity
    • Selectivity
    • Pharmacokinetics
    • Safety

The system also integrates toxicity and off-target risk prediction to avoid structural fragments associated with adverse effects, including liver injury.

According to the company, this integrated AI framework is designed to tackle so-called “hard-to-drug” or “undruggable” targets.

Leadership Commentary

Zhangming Niu, Founder and CEO of MindRank, described first patient dosing as a milestone not only for MDR-001 but also for AI-enabled drug development.

The company believes MDR-001 demonstrates how AI-driven discovery can accelerate innovation while delivering differentiated therapeutic candidates.

Why This Matters in the GLP-1 Landscape?

GLP-1 receptor agonists are reshaping the treatment landscape for obesity and type 2 diabetes.

However:

  • Many leading therapies are peptide-based
  • Several require injections
  • Oral small-molecule GLP-1RAs remain relatively limited

If MDR-001 can deliver strong efficacy with favorable tolerability as an oral small molecule, it could carve out meaningful differentiation in an increasingly competitive market.

About MindRank

MindRank is a clinical-stage biotechnology company focused on artificial intelligence-enabled drug discovery.

Its proprietary Molecule Pro platform integrates:

  • Artificial intelligence
  • Computational chemistry
  • Structural biology
  • Biology and medicine

The company’s mission is to accelerate the application of “AI for Science” and improve the efficiency and success rate of new drug development.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!